MISSION: STOP EARLY AGGRESSIVE
BREAST CANCER
CAPER-003
At CaperRX Inc., we are committed to unlocking the potential of first-in-class novel proprietary peptides that block CAPER as a fundamental cancer treatment at the cancer mutation DNA level, with a special focus on early aggressive breast cancer.
Our team of experienced professionals has a deep understanding of the medical needs of patients and has developed an innovative solution to address these needs. With our expertise and knowledge, we can provide solutions that are both cost-effective and transparent, while giving patients access to highly selective and safe peptides that can inhibit cancer growth and survival. We firmly believe that our solutions can significantly improve the quality of life and the survival of cancer patients and are dedicated to making that a reality.
MEET A HIGH UNMET NEED IN EARLY AGGRESSIVE BREAST CANCER
High unmet need for better, safer treatments for highly aggressive cancers that rapidly progress to patient death.
300,590 Breast Cancer patients projected to be diagnosed in 2023 with 43,700 Deaths.
30% of early Breast Cancer patients progress rapidly to metastatic disease, which doubles their risk of death.
Median Survival 12 months.
Unacceptable.
Killing Cancer Cells
We specialize in developing first-in-class peptides that selectively target and kill cancer cells, without any effect on normal cells. Our novel approach to cancer therapy is based on our observation of the Caper Cancer Protein, which is essential for cancer survival. By inhibiting the Caper Protein, we are able to kill cancer cells without any off-target side effects. We are a ground-floor opportunity for rapid development milestones and exit.
Our Management Team
Our team of scientists have over 15 years of experience in academia and has studied the role of CAPER in cancer initiation and progression to provide the foundation for future research.
Ted M. Kirsch, Ph.D.
Chief Executive Officer
Expertise in Global Strategic Development and Oncology and Infectious Disease.
Ted is a highly experienced leader with 25 years of Global Strategic Development, primarily in Oncology and Infectious Disease. He has been a project lead working globally with our small- to medium-sized business partners on projects of high corporate interest. His independent leadership has been established and recognized for its results in terms of timelines and budgets.
